BPC-157
Synthetic 15-aa sequence derived from a gastric juice protein. Reported anecdotally for soft-tissue and tendon recovery.
Start with a product
Pick what you have. We'll guide the rest.
Schedule, what to expect, side-effects to watch — built around your exact product.
Also: Body Protection Compound 157 · PL 14736
Synthetic 15-aa sequence derived from a gastric juice protein. Reported anecdotally for soft-tissue and tendon recovery.
Evidence Intelligence Score™
- Preclinical← current
- Pilot human
- RCT
- Multi-RCT
- Meta-analysis
Confidence aggregates eight dimensions of evidence — human data, safety maturity, mechanism, clinical readiness, momentum, consistency, long-term follow-up, and translational signal. It is a measure of what is known, not a recommendation. Methodology.
- Human evidenceWeight of RCT and observational data3.8
- Safety maturityFollow-up depth and adverse-event signal2.6
- Mechanism confidencePathway specificity and clarity6.5
- Clinical readinessDistance to physician-prescribable use2.8
- Research momentumRecency of indexed clinical evidence5.0
- Study consistencyEffect direction across cohorts5.8
- Long-term dataFollow-up beyond initial trial windows1.8
- Translational confidenceAnimal → human signal preservation4.5
Mechanistic and preclinical evidence is suggestive; controlled human trials are not yet on the index.
Translational confidence is limited until pre-registered human trials reproduce the preclinical signal.
Interactions outside listed contraindications, long-term safety, and effect heterogeneity across age and sex are not fully resolved.
Outlook: speculative. A grade upgrade requires controlled human evidence, not additional preclinical confirmation.
Tissue & joint repair
2 studies- moderateSikiric P, Seiwerth S, Rucman R, et al.Preclinical2018unreviewed
- moderateChang CH, Tsai WC, Hsu YH, Pang JHPreclinical2014unreviewed
Recovery time
1 study- moderateKrivic A, Anic T, Seiwerth S, Huljev D, Sikiric PPreclinical2008unreviewed
Gut health & inflammation
1 study- moderateSeiwerth S, Brcic L, Vuletic LB, et al.Preclinical2018unreviewed
Tissue & joint repair
1 regimenAnimal/in vitro data only. BPC-157 is not approved for human use in any jurisdiction.
Preclinical only; no standardized human protocol exists.
Recovery time
1 regimenAnimal model — not a human dosing reference. No FDA approval for BPC-157.
Animal study only; no validated human regimen.
Gut health & inflammation
1 regimenAnimal model. No human IBD trials. Not an approved therapy.
Preclinical only.
These are observed research regimens drawn from approved labels, clinical trials, or preclinical literature — not dosing recommendations. Suggestive, never prescriptive.
- —Long-term safety beyond reported study durations.
- —Effect size in populations under-represented in the cited trials.
- —Interactions with concomitant medications outside listed contraindications.
We surface uncertainty next to every claim. Suggestive, never prescriptive — discuss with a clinician.
6 brands across three tiers.
Compounded (US 503A)
1 brandPatient-specific preparations from US 503A compounding pharmacies. Require a valid prescription, not FDA-approved as finished drugs. Check the pharmacy's licence and the active ingredient's status on the FDA 503A bulks list.
Research-use only
5 brandsSold by chemical suppliers labelled 'for laboratory research only — not for human consumption'. No pharmaceutical-grade QC, no medical oversight. Listed for transparency.